Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
about
Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion.Final height in central precocious puberty after long term treatment with a slow release GnRH agonistPrecocious puberty in girls: early diagnosis of a slowly progressing variant.Recent Advances in the Treatment of Isosexual Precocious Puberty: Identifying all the problems.An increase in in vivo release of LHRH and precocious puberty by posterior hypothalamic lesions in female rhesus monkeys (Macaca mulatta)Safety of frequent venous blood sampling in a pediatric research populationCurrent pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties.Oncologic causes of precocious puberty.Advances in the Care of Transgender Children and Adolescents.Impact of sex steroids and their suppression on skeletal growth and maturation.Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity.Clinical applications of GnRH analogs.Importance of leuprolide acetate variable dosing for precocious puberty: a range of acceptable suppression.Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.Precocious puberty in children after traumatic brain injury.New insights in growth of phenylketonuric patients.
P2860
Q30437688-7353040D-64D9-4C12-AD24-A8D05A3F12FEQ33321113-99F8CBF7-20AD-4285-9E89-DDA616E0B981Q34799921-D28AAC53-7780-4788-AC12-89DD74FFA04DQ35625561-C189587B-57E9-44E6-8A1C-3ED7380BFDF0Q36283033-4135B418-995F-4CB2-BFE1-1A63E72143F6Q36389298-44287D69-7744-4B33-B4BB-A190D8D85E47Q37223386-D53A88AA-DB1C-40DF-9746-E6BDF72F6755Q38115615-D2C988D1-AF50-475C-ADF7-DB64150DAC10Q38789857-B0337652-4BE5-46BF-A8ED-1FF68DD28895Q38900046-472E9CA1-851A-49E2-B20F-57E8258DCA58Q39103915-8F6CC4ED-5D10-40C8-8E76-F868D65E2203Q39357860-0124C13A-510D-4B31-9AF9-F54BA8DB666CQ39564626-53FD4A15-9172-41D8-8D68-BB40D88454C5Q43272600-712FE681-5774-40A1-BB02-5C54A874C411Q44086638-AAE0F0DB-BBBE-4758-98E6-8B82E9C04DB9Q44636918-20C9E2B1-F6E3-4F3E-8B42-9201F8AF60FEQ45291081-04AE81A8-A9AB-4E02-8A72-D4A15A5CBF0A
P2860
Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年学术文章
@wuu
1986年学术文章
@zh-cn
1986年学术文章
@zh-hans
1986年学术文章
@zh-my
1986年学术文章
@zh-sg
1986年學術文章
@yue
1986年學術文章
@zh
1986年學術文章
@zh-hant
name
Use of a potent, long acting a ...... eatment of precocious puberty.
@en
Use of a potent, long acting a ...... eatment of precocious puberty.
@nl
type
label
Use of a potent, long acting a ...... eatment of precocious puberty.
@en
Use of a potent, long acting a ...... eatment of precocious puberty.
@nl
prefLabel
Use of a potent, long acting a ...... eatment of precocious puberty.
@en
Use of a potent, long acting a ...... eatment of precocious puberty.
@nl
P2093
P356
P1433
P1476
Use of a potent, long acting a ...... eatment of precocious puberty.
@en
P2093
Boepple PA
Crawford JD
Crigler JF Jr
Crowley WF Jr
Mansfield MJ
Wierman ME
P356
10.1210/EDRV-7-1-24
P577
1986-02-01T00:00:00Z